Pyrazolotriazines as kinase inhibitors

1. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of the following formula, or a pharmaceutically acceptable salt, or ester of said compound, in combination with at least one pharmaceutically acceptable carrier;

wherein:

R 1 is selected from the group consisting of H, alkyl, aryl, heteroaryl, heteroarylalkyl, arylalkyl, NR 6 R 7 , cycloalkyl and cycloalkylalkyl, wherein each of said alkyl, aryl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl and arylalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each being independently selected from the group consisting of halo, alkyl, aryl, heteroaryl, heterocyclyl, trifluoromethyl, OR 6 , NR 6 R 7 , SR 6 , SO 2 R 6 , CN, SO 2 N(R 6 R 7 ) and NO 2 ;

R 2 is alkyl, cycloalkyl, alkenyl, alkynyl, trifluoromethyl, —OR 7 , —SR 7 , hydroxyalkyl, haloalkyl, aryl, heteroaryl, halo, CN, formyl, nitro, alkylcarbonyl, aralkylcarbonyl, heteroaralkylcarbonyl, or -alkylene-N(R 6 R 9 ) (where R 8 and R 9 independently represent H or alkyl, or R 8 and R 9 taken together with the nitrogen in —N(R 8 R 9 ) form a five- to seven- membered heterocycle);

alkyl, alkylthio, aralkylthio, alkylsulfinyl, or aralkylsulfinyl;

R 4 is alkyl, cycloalkyl or heterocyclyl, wherein each of said alkyl, cycloalkyl and heterocyclyl can be unsubstituted or optionally independently substituted with 1–4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, trifluoromethyl, OR 6 , NR 6 R 7 , SR 6 , SO 2 R 6 , CN, SO 2 N(R6R7) and NO 2 ;

R 5 is H, alkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, heterocyclyl, acyl or heteroarylalkyl;

R 6 is H, alkyl or aryl;

R 7 is H or alkyl;

R 10 is halo, alkyl, hydroxyalkyl, trifluoromethyl, OR 6 , NR 8 R 7 , SR 6 , SO 2 R 6 , CN, SO 2 N(R 6 R 7 ) or NO 2 ; and

n is 0 to 4, and when n is 2–4, the n moieties can be the same or different, each being independently selected,

with the following provisos:

(i) that when R 2 is C 1 –C 4 alkyl and R 5 is H, then R 4 is not a C 1 –C 4 alkyl;

(ii) that when R 2 is halo, CN, formyl, nitro, alkylcarbonyl, aralkylcarbonyl, heteroaralkylcarbonyl, or -alkylene-N(R 8 R 9 ), then: (a) R 3 is not H, alkylthio, aralkylthio, alkylsulfinyl, aralkylsulfinyl, or —NR 4 R 5 , and (b) n is not 0; and

(iii) that when R 2 is alkyl, cycloalkyl, alkenyl or alkynyl, then R 3 is not NH(methyl), N ,N(dimethyl), NH(acetyl), N(methyl)(acetyl), H, alkyl, alkylthio, aralkylthio, alkylsulfinyl, or aralkylsulfinyl.

2. The pharmaceutical composition of claim 1 , additionally comprising one or more agents selected from the group consisting of cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.

3. A pharmaceutical composition comprising one or more compounds selected from:

or a pharmaceutically acceptable salt, or ester thereof.

4. The pharmaceutical composition of claim 3 , additionally comprising one or more agents selected from the group consisting of cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil , Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.